Skip to content
sellWeak

Richard M. Wright sold $1.2M of CLDX

SR. VP & CCO at Celldex Therapeutics, Inc.. 49,298 shares at an average of $24.00, traded Nov 13, 2025, filed Nov 17, 2025.

Warning score
38
Value
$1.2M
49,298 shares
Holdings after
20,833
-70% from before
From 52-week low
+57%
low $15.13, close $23.72
From 52-week high
-16%
high $28.14, as of Nov 13, 2025

Score components

  • Role
    Other
    +8
  • Trade size
    $1.2M at market
    +25
  • Share of holdings sold
    Sold 70% of holdings
    +20
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -0.9%, 3m -11.5%, 6m +16.2%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

CLDXOct 12, 2026 · close 29.43
Since filing Nov 17, 2025: +13.2%SPY +18.1% · excess -4.9%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001646423-25-000007, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 13, 2025MOption exercise
Common Stock
+6,876$9.02$62k27,709Nov 17, 2025
Nov 13, 2025MOption exercise
Common Stock
+26,672$10.38$277k54,381Nov 17, 2025
Nov 13, 2025MOption exercise
Common Stock
+15,750$22.48$354k70,131Nov 17, 2025
Nov 13, 2025SOpen-market sale
Common Stock
-49,298$24.00$1.2M20,833Nov 17, 2025
Nov 13, 2025MOption exercise
Incentive Stock Optionderivative
-6,876$0.00$00Nov 17, 2025
Nov 13, 2025MOption exercise
Incentive Stock Optionderivative
-26,672$0.00$00Nov 17, 2025
Nov 13, 2025MOption exercise
Incentive Stock Optionderivative
-15,750$0.00$07,875Nov 17, 2025

Related signals

Other insiders at Celldex Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
CLDXsell
Celldex Therapeutics, Inc.
Freddy A. Jimenez
SVP & GENERAL COUNSEL
$121k
4,166 shares
-12%
15Weak
CLDXsell
Celldex Therapeutics, Inc.
Freddy A. Jimenez
SVP & GENERAL COUNSEL
$19k
771 shares
-2%
45Moderate
CLDXbuy
Celldex Therapeutics, Inc.
Anthony S Marucci
PRESIDENT & CEO
$308k
11,500 shares
+40%
60Notable
CLDXsell 6
Celldex Therapeutics, Inc.
Elizabeth Crowley
SR. VP & CPDO
$1.0M
30,000 shares
-77%
52Moderate
CLDXsell 6
Celldex Therapeutics, Inc.
Samuel Bates Martin
SVP AND CFO
$608k
17,172 shares
-38%
75Notable
CLDXsell 7
Celldex Therapeutics, Inc.
Diane C. Young
SVP, CHIEF MEDICAL OFFICER
$1.6M
45,000 shares
-96%
53Moderate
CLDXsell 7
Celldex Therapeutics, Inc.
Elizabeth Crowley
SR. VP & CPDO
$526k
15,000 shares
-62%
33Weak
CLDXsell 7
Celldex Therapeutics, Inc.
Freddy A. Jimenez
SVP & GENERAL COUNSEL
$269k
8,006 shares
-24%
60Notable
CLDXsell 7
Celldex Therapeutics, Inc.
Richard M. Wright
SR. VP & CCO
$1.6M
46,844 shares
-69%
60Notable
CLDXsell 7
Celldex Therapeutics, Inc.
Margo Heath-Chiozzi
SVP OF REGULATORY AFFAIRS
$2.0M
58,369 shares
-81%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Richard M. Wright sold $1.2M of CLDX | InsiderTell